Correction: BMC Genomics 24, 212 (2023)

https://doi.org/10.1186/s12864-023-09310-8

Following publication of the original article [1], it was reported that supplementary tables 1, 2 and 8 were missing from the published article. Additionally, the incorrect versions of Figs. 1 and 4 were published. The updated figures and supplementary files are included in this Correction and the original article has been updated.

Fig. 1
figure 1

Select pedigrees from the eoRCC patient cohort and enrichment of predicted pathogenic variants in DNA repair genes in the cohort. A-E. Pedigrees of eoRCC patients with variants in: A—POLD1 and POLH; B—POLE; C—ATM; D—RRM2B and BCL2L1; E—OGG1, NEIL3 and UBR5. F. Summary of variants in genes and pathways, identifed in the cohort. In color—number of variants identifed for each gene. For detailed information, see Supplementary tables 1 and 2

Fig. 4
figure 2

Renal tumors carrying polymerase variants showed high TMB, MSS, and no LOH. A. Percent alteration frequency in 897 tumors from TCGA in diferent histological types of RCC: chromophobe (n = 66), ccRCC—clear cell renal cell carcinoma (n = 538), ccRCC (hyper)—hypermutated samples (n = 12), papillary (n = 293). B. TMB and MSS data are presented for Pt #1 (POLD1 V759I, POLH G209V) and Pt #2 (POLE W1624X). C. Tumor and normal Sanger sequencing for variants in Pt #1 (POLD1 V759I, POLH G209V) and Pt #2 (POLE W1624X) showing no LOH. Arrows show variants of interest on sequencing tracks